GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Biological: Pandemic influenza vaccine GSK2340272A
- First Posted Date
- 2009-09-03
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 157
- Registration Number
- NCT00971321
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain
Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age
Phase 2
Completed
- Conditions
- Hepatitis BTetanusDiphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria MeniPoliomyelitisDiphtheriaHaemophilus Influenzae Type bAcellular Pertussis
- Interventions
- Biological: Infanrix hexa™Biological: 10-valent pneumococcal vaccine (GSK 1024850A)Biological: GSK2202083A vaccineBiological: Menjugate®
- First Posted Date
- 2009-09-02
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 421
- Registration Number
- NCT00970307
- Locations
- 🇵🇱
GSK Investigational Site, Wroclaw, Poland
Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean Infants
Phase 4
Completed
- Conditions
- Infections, RotavirusRotavirus Vaccines
- Interventions
- Biological: Rotarix ™Biological: Placebo
- First Posted Date
- 2009-09-01
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 684
- Registration Number
- NCT00969228
- Locations
- 🇰🇷
GSK Investigational Site, Suwon, Kyonggi-do, Korea, Republic of
Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM
Phase 3
Completed
- Conditions
- MumpsMeaslesRubellaVaricella
- Interventions
- Biological: GSK Biological's investigational MMRV vaccine 208136Biological: Priorix™Biological: Varilrix™
- First Posted Date
- 2009-09-01
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 450
- Registration Number
- NCT00969436
- Locations
- 🇮🇳
GSK Investigational Site, Pune, India
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: GSK investigational vaccine GSK2340272A
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 240
- Registration Number
- NCT00968526
- Locations
- 🇧🇪
GSK Investigational Site, Wilrijk, Belgium
Study in Neuropathic Pain Patients With Peripheral Nerve Injury
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 168
- Registration Number
- NCT00969059
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: GSK investigational vaccine GSK2340272ABiological: GSK investigational vaccine GSK2340269A
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 130
- Registration Number
- NCT00968539
- Locations
- 🇧🇪
GSK Investigational Site, Gent, Belgium
Extension Study of GI198745 to Treat Benign Prostatic Hyperplasia
Phase 2
Completed
- Conditions
- Benign Prostatic HyperplasiaProstatic Hyperplasia
- Interventions
- Drug: GI198745 0.05mgDrug: GI198745 0.5mgDrug: GI198745 2.5mg
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2010-09-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 121
- Registration Number
- NCT00969072
Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Biological: Pandemrix (Influenza vaccine GSK2340272A)Biological: Fluarix™Biological: Placebo
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 168
- Registration Number
- NCT00968890
- Locations
- 🇸🇪
GSK Investigational Site, Örebro, Sweden
Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: Pandemic influenza vaccine GSK2340272A
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2018-02-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 210
- Registration Number
- NCT00964158
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain
© Copyright 2025. All Rights Reserved by MedPath